ASCO Personalized Meds Project Aims To Develop Outcomes Data For Off-Label Uses
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients could receive cancer treatment at reduced or no cost for medicines selected based on molecular testing, and in return their data would be entered into a prospective registry, under a project ASCO is developing.
You may also be interested in...
AstraZeneca, Pfizer, U.K. Charity’s Joint Lung Cancer Trial Aims To Make Tumor Genetic Testing Routine
A pioneering approach to trialing targeted medicines in late-stage NSCLC is being launched throughout Britain, giving researchers unprecedented access to libraries of drugs developed by AstraZeneca and Pfizer, allowing several to be tested at the same time within one trial.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.